10:01 AM EDT, 03/23/2026 (MT Newswires) -- Medtronic ( MDT ) said Monday that the US Food and Drug Administration approved an expanded indication for the OmniaSecure defibrillation lead to include placement in the left bundle branch area for conduction system pacing.

Patients who require cardiac resynchronization may also benefit from a therapy combining conduction system pacing with left-ventricular pacing, the company said.

The FDA approval was based on data from a global trial that demonstrated the lead's safety and effectiveness in left bundle branch area pacing, Medtronic ( MDT ) added.

OmniaSecure defibrillation lead was launched in the US in January after the FDA approved it for placement in traditional locations in the right ventricle.

Price: 86.79, Change: +0.63, Percent Change: +0.73